10.85
+0.217(+2.04%)
Currency In USD
| Previous Close | 10.63 |
| Open | 10.7 |
| Day High | 11.11 |
| Day Low | 10.7 |
| 52-Week High | 21.5 |
| 52-Week Low | 5.2 |
| Volume | 12,617 |
| Average Volume | 130,188 |
| Market Cap | 92.34M |
| PE | -0.42 |
| EPS | -26 |
| Moving Average 50 Days | 9.7 |
| Moving Average 200 Days | 8.82 |
| Change | 0.22 |
If you invested $1000 in Sutro Biopharma, Inc. (STRO) since IPO date, it would be worth $71.36 as of January 14, 2026 at a share price of $10.847. Whereas If you bought $1000 worth of Sutro Biopharma, Inc. (STRO) shares 5 years ago, it would be worth $41.83 as of January 14, 2026 at a share price of $10.847.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire Inc.
Dec 17, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 16, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced